MyPeBS (My Personalized Breast Screening)
Research type
Research Study
Full title
MyPeBS International Randomized Study Comparing personalized, Risk- Stratified to Standard Breast Cancer Screening In Women Aged 40-70
IRAS ID
251642
Contact name
Fiona Gilbert
Contact email
Sponsor organisation
UNICANCER
Clinicaltrials.gov Identifier
2018-A00535-50, ID RCB
Duration of Study in the UK
7 years, 0 months, 31 days
Research summary
MyPeBS is a European randomized, open-label, multicentre study assessing the effectiveness of a risk-based breast cancer screening strategy compared to standard screening (according to the current national guidelines in each participating country), in detecting stage 2 or higher breast cancers.
MyPeBS addresses the crucial and timely question of the future of breast cancer screening in Europe.Indeed current standard mammographic screening, with entry stratified by age alone, has recently been largely questioned. Despite a demonstrated mean 20% reduction in breast cancer-specific mortality, together
with reduction of late-stage disease in women older than 50, mammographic screening is associated with potential harms including false positive recalls and over-diagnosis.In this study personalized screening strategies, based on an estimate of individual risk levels, determined by demographic, clinical data (including breast density) and genetic markers of susceptibility could potentially improve the individual benefit/harms ratio of screening (earlier cancer detection and less intensive treatments in high risk women, less false positives and over-diagnoses in low risk ones), and increase the cost-efficacy of the screening programme.
Women from the general population who are eligible for the national breast screening programme, without a personal history of breast cancer or a high risk of breast cancer will be eligible. Women entering the trial will be randomly allocated to either continue on the usual screening path or have mammographic screening at a frequency determined by a personal risk score. Participants will be differentially screened for 4 years and then, after an end-of-study mammogram, they will return to the routine screening practice. The main study end point will be measured at the end of the four years of intervention. Furthermore, follow up data will be collected for 15 years from study entry for evaluation of long-term cumulative breast cancer incidence and breast cancer-specific survival.
REC name
London - Chelsea Research Ethics Committee
REC reference
18/LO/2039
Date of REC Opinion
18 Dec 2018
REC opinion
Favourable Opinion